Pairing Hyrax Biosciences' Exatype platform with Roche's KAPA HyperCap workflow provides an integrated, end-to-end solution from sample prep through to data analysis, interpretation and reporting.
Exatype supports the automated analysis of data generated from Roche’s KAPA HyperCap SARS-CoV-2 Panel (RUO) thereby making sequencing for SARS-CoV-2 genomic surveillance faster, cheaper and more accurate.
Experience the full workflow - a demo dataset is included in the welcome email upon signup, but you are welcome to use your own Roche KAPA HyperCap SARS-CoV-2 data instead.
Report variant prevalences with confidence
Harness the power of Exatype’s algorithms in detecting low abundance variants e.g. surveillance studies and detection of dual-infection
Intuitive drag-and-drop interface means minimal end-user input needed to analyse data
Scale up with ease using Hyrax Biosciences’ streamlined and secure, cloud-based IT infrastructure
Confidently detect and report variants with the Exatype platform
Report your findings faster by on-cloud parallel processing using the intuitive interface of the Exatype platform
Hyrax Biosciences’ proven expertise in viral sequence and reporting offers reliable SARS-CoV-2 surveillance
APIs enable direct integration with sequencers and/or LIMS (contact us for more information)
Our modular platform can analyse and interpret sequence data from an ever-expanding range of applications, including:
Genotyping and drug-resistance testing in infectious diseases e.g. HIV, TB, SARS-CoV-2.
Multi-target diagnostics, e.g. infectious disease panels.
Tumour profiling and drug-susceptibility testing in cancer.
Low abundance variant detection e.g. detecting mixed infections or the detection of biomarkers in liquid biopsies.